請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/71286
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 黃敏銓(Min-Chuan Huang) | |
dc.contributor.author | Szu-Min Tu | en |
dc.contributor.author | 杜思旻 | zh_TW |
dc.date.accessioned | 2021-06-17T05:02:55Z | - |
dc.date.available | 2023-08-01 | |
dc.date.copyright | 2018-08-01 | |
dc.date.issued | 2018 | |
dc.date.submitted | 2018-07-24 | |
dc.identifier.citation | 1. L., S.R., M.K. D., and J. Ahmedin, Cancer statistics, 2018. CA: A Cancer Journal for Clinicians, 2018. 68(1): p. 7-30.
2. Woolgar, J.A., et al., Cervical lymph node metastasis in oral cancer: the importance of even microscopic extracapsular spread. Oral Oncology, 2003. 39(2): p. 130-137. 3. Pignon, J.-P., et al., Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiotherapy and Oncology, 2009. 92(1): p. 4-14. 4. Zimmermann, M., et al., The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications. Radiation Oncology (London, England), 2006. 1: p. 11-11. 5. Boyle, J.O., et al., The Incidence of <em>p53</em> Mutations Increases with Progression of Head and Neck Cancer. Cancer Research, 1993. 53(19): p. 4477-4480. 6. Tan, M., J.N. Myers, and N. Agrawal, Oral Cavity and Oropharyngeal Squamous Cell Carcinoma Genomics. Otolaryngologic Clinics of North America, 2013. 46(4): p. 545-566. 7. Ran, X. and K. Yang, Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectives. Drug Design, Development and Therapy, 2017. 11: p. 2007-2014. 8. Denaro, N., et al., State-of-the-Art and Emerging Treatment Options in the Management of Head and Neck Cancer: News from 2013. Oncology, 2014. 86(4): p. 212-229. 9. Spiro, R.G., Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. Glycobiology, 2002. 12(4): p. 43R-56R. 10. Breitling, J. and M. Aebi, N-Linked Protein Glycosylation in the Endoplasmic Reticulum. Cold Spring Harbor Perspectives in Biology, 2013. 5(8): p. a013359. 11. Bennett, E.P., et al., Control of mucin-type O-glycosylation: A classification of the polypeptide GalNAc-transferase gene family. Glycobiology, 2012. 22(6): p. 736-756. 12. Hakomori, S.I. and W.T. Murakami, Glycolipids of hamster fibroblasts and derived malignant-transformed cell lines. Proceedings of the National Academy of Sciences of the United States of America, 1968. 59(1): p. 254-261. 13. Hakomori, S., Glycosylation defining cancer malignancy: New wine in an old bottle. Proceedings of the National Academy of Sciences of the United States of America, 2002. 99(16): p. 10231-10233. 14. Chen, C.-H., et al., MUC20 overexpression predicts poor prognosis and enhances EGF-induced malignant phenotypes via activation of the EGFR–STAT3 pathway in endometrial cancer. Gynecologic Oncology, 2013. 128(3): p. 560-567. 15. H., J.P., K. Daniel, and P.N. H., Mucin‐type O‐glycosylation – putting the pieces together. The FEBS Journal, 2010. 277(1): p. 81-94. 16. Ragupathi, G., Carbohydrate antigens as targets for active specific immunotherapy. Cancer Immunology, Immunotherapy, 1996. 43(3): p. 152-157. 17. Helenius, A., Aebi, and Markus, Intracellular Functions of N-Linked Glycans. Science, 2001. 291(5512): p. 2364-2369. 18. Locker, G.Y., et al., ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer. Journal of Clinical Oncology, 2006. 24(33): p. 5313-5327. 19. Fu, J., et al., Loss of intestinal core 1–derived O-glycans causes spontaneous colitis in mice. The Journal of Clinical Investigation, 2011. 121(4): p. 1657-1666. 20. Kudo, T., et al., C1galt1-deficient mice exhibit thrombocytopenia due to abnormal terminal differentiation of megakaryocytes. Blood, 2013. 122(9): p. 1649-1657. 21. Alexander, W.S., et al., Thrombocytopenia and kidney disease in mice with a mutation in the C1galt1 gene. Proceedings of the National Academy of Sciences of the United States of America, 2006. 103(44): p. 16442-16447. 22. Guzman-Aranguez, A., et al., Targeted Disruption of Core 1 β1,3-galactosyltransferase (C1galt1) Induces Apical Endocytic Trafficking in Human Corneal Keratinocytes. PLoS ONE, 2012. 7(5): p. e36628. 23. Wu, Y.-M., et al., C1GALT1 Enhances Proliferation of Hepatocellular Carcinoma Cells via Modulating MET Glycosylation and Dimerization. Cancer Research, 2013. 73(17): p. 5580-5590. 24. Hung, J.-S., et al., C1GALT1 overexpression promotes the invasive behavior of colon cancer cells through modifying O-glycosylation of FGFR2. Oncotarget, 2014. 5(8): p. 2096-2106. 25. Cazet, A., et al., Tumour-associated carbohydrate antigens in breast cancer. Breast Cancer Research : BCR, 2010. 12(3): p. 204-204. 26. Patil, S.A., et al., Overexpression of α2,3sialyl T-antigen in breast cancer determined by miniaturized glycosyltransferase assays and confirmed using tissue microarray immunohistochemical analysis. Glycoconjugate journal, 2014. 31(0): p. 509-521. 27. Brockhausen, I., Mucin-type O-glycans in human colon and breast cancer: glycodynamics and functions. EMBO Reports, 2006. 7(6): p. 599-604. 28. Whitehouse, C., et al., A Transfected Sialyltransferase That Is Elevated in Breast Cancer and Localizes to the medial/trans-Golgi Apparatus Inhibits the Development of core-2–based O-Glycans. The Journal of Cell Biology, 1997. 137(6): p. 1229-1241. 29. Inka, B., et al., Mechanisms Underlying Aberrant Glycosylation of MUC1 Mucin in Breast Cancer Cells. European Journal of Biochemistry, 1995. 233(2): p. 607-617. 30. Yu, L.-G., et al., Galectin-3 Interaction with Thomsen-Friedenreich Disaccharide on Cancer-associated MUC1 Causes Increased Cancer Cell Endothelial Adhesion. Journal of Biological Chemistry, 2007. 282(1): p. 773-781. 31. Tsai, C.-H., et al., Metastatic Progression of Prostate Cancer Is Mediated by Autonomous Binding of Galectin-4-<em>O</em>-Glycan to Cancer Cells. Cancer Research, 2016. 76(19): p. 5756-5767. 32. Lin, M.-C., et al., C1GALT1 predicts poor prognosis and is a potential therapeutic target in head and neck cancer. Oncogene, 2018. 33. Joyce, J.A. and J.W. Pollard, Microenvironmental regulation of metastasis. Nature reviews. Cancer, 2009. 9(4): p. 239-252. 34. Quail, D.F. and J.A. Joyce, Microenvironmental regulation of tumor progression and metastasis. Nature medicine, 2013. 19(11): p. 1423-1437. 35. Balkwill, F. and A. Mantovani, Inflammation and cancer: back to Virchow? The Lancet, 2001. 357(9255): p. 539-545. 36. Sangiovanni, A., et al., Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology, 2004. 126(4): p. 1005-1014. 37. Beaugerie, L., et al., Risk of Colorectal High-Grade Dysplasia and Cancer in a Prospective Observational Cohort of Patients With Inflammatory Bowel Disease. Gastroenterology, 2013. 145(1): p. 166-175.e8. 38. Biswas, S.K. and A. Mantovani, Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nature Immunology, 2010. 11: p. 889. 39. Qian, B. and J.W. Pollard, Macrophage Diversity Enhances Tumor Progression and Metastasis. Cell, 2010. 141(1): p. 39-51. 40. Goswami, S., et al., Macrophages Promote the Invasion of Breast Carcinoma Cells via a Colony-Stimulating Factor-1/Epidermal Growth Factor Paracrine Loop. Cancer Research, 2005. 65(12): p. 5278-5283. 41. Coniglio, S.J., et al., Microglial Stimulation of Glioblastoma Invasion Involves Epidermal Growth Factor Receptor (EGFR) and Colony Stimulating Factor 1 Receptor (CSF-1R) Signaling. Molecular Medicine, 2012. 18(1): p. 519-527. 42. Lewis, C. and C. Murdoch, Macrophage Responses to Hypoxia : Implications for Tumor Progression and Anti-Cancer Therapies. The American Journal of Pathology, 2005. 167(3): p. 627-635. 43. Jablonski, K.A., et al., Novel Markers to Delineate Murine M1 and M2 Macrophages. PLOS ONE, 2015. 10(12): p. e0145342. 44. Wan, K.T., C.B. Hyun, and C.Y. Keun, Production of Soluble Human Interleukin-6 in Cytoplasm by Fed-Batch Culture of Recombinant E. coli. Biotechnology Progress, 2005. 21(2): p. 524-531. 45. Medzihradszky, K.F., K. Kaasik, and R.J. Chalkley, Tissue-Specific Glycosylation at the Glycopeptide Level. Molecular & Cellular Proteomics : MCP, 2015. 14(8): p. 2103-2110. 46. Jakubzick, C.V., G.J. Randolph, and P.M. Henson, Monocyte differentiation and antigen-presenting functions. Nature Reviews Immunology, 2017. 17: p. 349. 47. Shigeru, T., et al., Establishment and characterization of a human acute monocytic leukemia cell line (THP‐1). International Journal of Cancer, 1980. 26(2): p. 171-176. 48. Qin, Z., The use of THP-1 cells as a model for mimicking the function and regulation of monocytes and macrophages in the vasculature. Atherosclerosis, 2012. 221(1): p. 2-11. 49. Shiratori, H., et al., THP-1 and human peripheral blood mononuclear cell-derived macrophages differ in their capacity to polarize in vitro. Molecular Immunology, 2017. 88: p. 58-68. 50. Solinas, G., et al., Tumor-Conditioned Macrophages Secrete Migration-Stimulating Factor: A New Marker for M2-Polarization, Influencing Tumor Cell Motility. The Journal of Immunology, 2010. 185(1): p. 642-652. 51. Chimal-Ramírez, G.K., et al., Monocyte Differentiation towards Protumor Activity Does Not Correlate with M1 or M2 Phenotypes. Journal of Immunology Research, 2016. 2016: p. 6031486. 52. Fan, F., et al., Macrophage conditioned medium promotes colorectal cancer stem cell phenotype via the hedgehog signaling pathway. PLOS ONE, 2018. 13(1): p. e0190070. 53. Kamoshida, G., et al., Monocyte differentiation induced by co-culture with tumor cells involves RGD-dependent cell adhesion to extracellular matrix. Cancer Letters, 2012. 315(2): p. 145-152. 54. Yang, J., et al., Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases. Biomarker Research, 2014. 2: p. 1-1. 55. Kubala, M., V. Placencio, and Y. DeClerck, Plasminogen activator inhibitor-1 increases migration of monocytes to the tumor and skews their differentiation towards M2 macrophage phenotype (TUM6P.1002). The Journal of Immunology, 2015. 194(1 Supplement): p. 141.26-141.26. 56. Kubala, M.H., V.R. Placencio, and Y.A. DeClerck, Abstract 3061: Tumor-derived PAI-1 promotes macrophage M2 polarization by stimulating an autocrine IL-6 /STAT3 pathway. Cancer Research, 2017. 77(13 Supplement): p. 3061-3061. 57. Ruiz-Rosado, J.d.D., et al., MIF Promotes Classical Activation and Conversion of Inflammatory Ly6C(high) Monocytes into TipDCs during Murine Toxoplasmosis. Mediators of inflammation, 2016. 2016: p. 9101762-9101762. 58. Chomarat, P., et al., IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nature Immunology, 2000. 1: p. 510. 59. Wang, Q., et al., Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2α. Nature Communications, 2018. 9(1): p. 559. 60. Jackson, A.L., et al., Expression profiling reveals off-target gene regulation by RNAi. Nature Biotechnology, 2003. 21: p. 635. 61. Libermann, T.A. and D. Baltimore, Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Molecular and Cellular Biology, 1990. 10(5): p. 2327-2334. 62. Kishimoto, T., S. Akira, and T. Taga, Interleukin-6 and its receptor: a paradigm for cytokines. Science, 1992. 258(5082): p. 593-597. 63. Tanaka, T., M. Narazaki, and T. Kishimoto, IL-6 in Inflammation, Immunity, and Disease. Cold Spring Harbor Perspectives in Biology, 2014. 6(10): p. a016295. 64. Szczepanski, M.J., et al., Triggering of Toll-like Receptor 4 Expressed on Human Head and Neck Squamous Cell Carcinoma Promotes Tumor Development and Protects the Tumor from Immune Attack. Cancer research, 2009. 69(7): p. 3105-3113. 65. Santhanam, U., et al., Post-translational modifications of human interleukin-6. Archives of Biochemistry and Biophysics, 1989. 274(1): p. 161-170. 66. SolÁ, R.J. and K.A.I. Griebenow, Effects of Glycosylation on the Stability of Protein Pharmaceuticals. Journal of pharmaceutical sciences, 2009. 98(4): p. 1223-1245. 67. Goth, C.K., et al., Site-specific O-Glycosylation by Polypeptide N-Acetylgalactosaminyltransferase 2 (GalNAc-transferase T2) Co-regulates β(1)-Adrenergic Receptor N-terminal Cleavage. The Journal of Biological Chemistry, 2017. 292(11): p. 4714-4726. 68. Goth, C.K., et al., A systematic study of modulation of ADAM-mediated ectodomain shedding by site-specific O-glycosylation. Proceedings of the National Academy of Sciences of the United States of America, 2015. 112(47): p. 14623-14628. 69. Fisher, D.T., M.M. Appenheimer, and S.S. Evans, The Two Faces of IL-6 in the Tumor Microenvironment. Seminars in immunology, 2014. 26(1): p. 38-47. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/71286 | - |
dc.description.abstract | 頭頸癌在台灣十大癌症死亡率中排名第五,治療後復發轉移率高是造成頭頸癌死亡率高居不下的原因之一,頭頸癌患者整體五年存活率低於50%。異常醣化作用 (glycosylation) 會影響許多腫瘤細胞特性。Core 1 β1,3-galactosyltransferase (C1GALT1) 會調節氧型醣化作用 (O-glycosylation),並促進頭頸癌、卵巢癌、乳癌的惡性特性。腫瘤細胞會分泌各種細胞激素至腫瘤微環境內,影響單核球細胞的移行與分化。已有研究顯示,腫瘤相關巨噬細胞會影響腫瘤細胞的生長、新血管生成和腫瘤微環境細胞外基質的重塑。此外,在臨床上也顯示腫瘤相關巨噬細胞與腫瘤的惡性程度和不良的預後相關。然而,頭頸癌細胞中的氧型醣基化對於單核球分化的影響目前還是未知的,因此,在本研究中我們探討在SAS頭頸癌細胞中由C1GALT1調控的氧型醣基化對單核球細胞分化的影響。首先我們利用免疫組織染色對41位頭頸癌患者的腫瘤切片進行分析,結果顯示當C1GALT1表現量較高時,在腫瘤附近的腫瘤相關巨噬細胞與第二型巨噬細胞數量皆較少。接著,我們利用流式細胞儀分析剔除C1GALT1後腫瘤細胞表面的醣型結構變化,證實剔除C1GALT1會影響腫瘤細胞的醣化作用,造成Tn antigen大量累積。為了模擬腫瘤微環境,我們使用SAS細胞的條件培養基 (Conditioned media) 分別刺激THP-1單核球細胞株與小鼠骨髓來源單核球細胞,分析單核球細胞的分化趨勢,結果顯示SAS細胞條件培養基會促進單核球細胞分化為第一型巨噬細胞,且抑制SAS細胞中C1GALT1的表現會加強此分化趨勢。另外,我們也證實了在SAS細胞中抑制C1GALT1的表現,會影響頭頸癌細胞中IL-6、CSF-1等細胞激素的mRNA表現量。最後我們構築了pET-29b/MPB-IL-6質體 (plasmid),藉由大腸桿菌誘導產生MBP-IL-6重組蛋白,並使用質譜儀分析進行確認。未來,將會進一步製備IL-6多株抗體 (polyclonal antibody),應用於IL-6的純化,期望可進一步研究不同醣型 (glycoform) 的IL-6在頭頸癌與免疫作用中扮演的角色。 | zh_TW |
dc.description.abstract | Head and neck cancer is the fifth of leading cause of cancer-related deaths in Taiwan. The majority of head and neck cancer treatment failures arise from metastasis and recurrence after surgical resection. The overall five-year survival rate remains less than 50%. Core 1 β1,3-galactosyltransferase (C1GALT1) controls the crucial step of mucin-type O-glycosylation. It has been reported to promote the malignant character of head and neck, bladder and breast cancer cells. Tumor cells secrete various cytokines into the tumor microenvironment (TME), recruit monocytes and regulate their differentiation to tumor-associated macrophages. In previous study, tumor-associated macrophages (TAMs) support diverse phenotypes within the primary tumor, including growth, angiogenesis and remodeling the extracellular matrix in TME. However, the effect of O-glycosylation in head and neck cancer cells on monocyte differentiation remains unknown. This study aims to determine the effects of C1GALT1-mediated O-glycosylation in SAS cells on monocyte differentiation. First, we analyzed forty-one sections of tumors from head and neck cancer patients by immunohistochemistry. The result showed that tumors expressing higher C1GALT1 contained more TAMs and M2 macrophages. Next, we showed that knockout of C1GALT1 changed the glycan structure on cell surfaces. To mimic the TME, we used conditioned media (CM) from SAS cells to induce differentiation of THP-1 and mouse bone marrow derived monocytes. Results showed that CM from SAS cells was able to skew monocytes into M1 macrophages, and knockdown of C1GALT1 enhanced this effect. Furthermore, knockdown of C1GALT1 downregulated IL-6 and CSF1 mRNA levels. In addition, the maltose-binding protein (MBP)-IL-6 recombinant protein was expressed in E.coli and we confirmed its identity by using mass spectrometry. In the future, polyclonal antibodies against IL-6 will be further prepared for the purification of IL-6. We hope to further study the role of different IL-6 glycoforms in the immunity of head and neck cancer. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T05:02:55Z (GMT). No. of bitstreams: 1 ntu-107-R05446002-1.pdf: 7225544 bytes, checksum: e0422e5644e5c3c4b892bbb35d6d047e (MD5) Previous issue date: 2018 | en |
dc.description.tableofcontents | 口試委員會審定書 i
致謝 ii 中文摘要 iii Abstract v 目 錄 vii 圖目錄 ix 表目錄 x 第一章 前言 1 1.1 頭頸部口腔鱗狀上皮細胞癌 1 1.2 蛋白質的醣化作用 (Protein glycosylation) 2 1.3 蛋白質的醣化作用與癌症的關係 2 1.4 Core 1 β1,3-galactosyltransferase (C1GALT1) 的簡介 3 1.5 C1GALT1與癌症 3 1.6 腫瘤微環境 4 1.7 腫瘤與免疫 4 1.8 腫瘤相關巨噬細胞 5 第二章 研究目標 7 第三章 材料與方法 8 3.1 細胞株與細胞培養 8 3.2 小鼠骨髓來源巨噬細胞分離與培養 (Bone marrow derived monocytes, BMDM) 8 3.3 流式細胞儀 9 3.4 siRNA抑制C1GALT1表現 10 3.5 mRNA 萃取 10 3.6 反轉錄-聚合酶鏈鎖反應 (Revers Transcription Polymerase Chain Reaction, RT-PCR) 合成cDNA 10 3.7 即時定量-聚合酶鏈鎖反應 (Real time Polymerase Chain Reaction, Real time-PCR) 11 3.8 細胞蛋白質萃取與定量 11 3.9 人類細胞激素試驗 (Human Cytokine Array) 12 3.10 西方墨點法 12 3.11 臨床檢體收集與免疫組織化學染色法 13 3.12 構築pET-29b/MBP-IL6質體 13 3.13 生產MBP-IL6 重組蛋白 14 3.14 純化MBP-IL6 重組蛋白與MS鑑定 15 3.15 統計分析 15 第四章 結果 16 4.1 免疫組織染色顯示腫瘤檢體中C1GALT1與CD68、CD163具有負向相關。 16 4.2 剔除C1GALT1表現改變SAS頭頸癌細胞表面醣類結構型態。 16 4.3 剔除C1GALT1表現改變MKN45胃癌細胞表面醣類結構型態。 17 4.4 SAS頭頸癌細胞的Conditioned media會促進THP-1單核球細胞株往第一型巨噬細胞分化。 17 4.5 SAS頭頸癌細胞的Conditioned media會促進小鼠分離的初級單核球細胞往第一型巨噬細胞分化,且抑制C1GALT1的表現會加強此分化趨勢。 18 4.6 抑制C1GALT的表現會影響SAS細胞中細胞激素的表現量。 19 4.7 抑制C1GALT的表現會影響頭頸癌細胞中細胞激素的mRNA表現量。 20 4.8 抑制C1GALT的表現會降低SAS頭頸癌細胞中IL-6的蛋白表現量。 20 4.9 構築pET-29b/MBP-IL-6質體。 21 4.10 誘導表現MBP-IL6重組蛋白和純化。 21 第五章 討論 22 第六章 參考文獻 27 圖一、以C1GALT1、CD68、CD163抗體分別進行免疫染色,偵測病人C1GALT1、腫瘤相關巨噬細胞與第二型巨噬細胞在腫瘤檢體中(n=41)的表現情形,並統計兩兩之間的相關性。 34 圖二、流式細胞儀染凝集素分析剔除C1GALT1表現後SAS頭頸癌細胞表面醣類結構的變化。 39 圖三、流式細胞儀染凝集素分析剔除C1GALT1表現後MKN45胃癌細胞表面醣類結構的變化。 44 圖四、在由THP-1分化的巨噬細胞中,第一型與第二型巨噬細胞相關基因的mRNA表現量。 47 圖五、在由小鼠BMDM分化的巨噬細胞中,第一型與第二型巨噬細胞相關基因的mRNA表現量。 48 圖六、流式細胞儀分析由小鼠BMDM分化的巨噬細胞中,CD38與Egr2蛋白的表現量。 50 圖七、抑制C1GALT1表現,對SAS細胞中36種細胞激素表現量的影響。 51 圖八、3種頭頸癌細胞中,抑制C1GALT1表現後6種細胞激素的mRNA表現量。 53 圖九、抑制C1GALT1表現對SAS頭頸癌細胞介白素6 (interleukin 6, IL-6) 表現的影響。 54 圖十、構築pET-29b/MBP-IL-6質體。 55 圖十一、誘導表現MBP-IL-6重組蛋白和純化,並以MS進行確認。 56 圖十二、剔除C1GALT1對SAS頭頸癌細胞與MKN45胃癌細胞其表面醣蛋白型態的影響與比較。 57 表一、流式細胞儀分析所使用之抗體 58 表二、siRNA序列 59 表三、即時定量聚合酶連鎖反應 (Real-time Polymerase Chain Reaction, Real-time-PCR)引子 (Primer)序列 60 表四、西方墨點法 (Western blot analysis)所使用之抗體 61 | |
dc.language.iso | zh-TW | |
dc.title | C1GALT1調控的氧型醣化在SAS細胞中對單核球細胞分化的影響 | zh_TW |
dc.title | Effects of C1GALT1-mediated O-glycosylation in SAS cells on
monocyte differentiation. | en |
dc.type | Thesis | |
dc.date.schoolyear | 106-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 林玫君(Mei-Chun Lin) | |
dc.contributor.oralexamcommittee | 林能裕(Neng-Yu Lin),莊雅婷 | |
dc.subject.keyword | 頭頸癌,醣化作用,C1GALT1,單核球分化,IL-6, | zh_TW |
dc.subject.keyword | head and neck cancer,glycosylation,C1GALT1,monocyte differentiation,IL-6, | en |
dc.relation.page | 61 | |
dc.identifier.doi | 10.6342/NTU201801801 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2018-07-24 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 解剖學暨細胞生物學研究所 | zh_TW |
顯示於系所單位: | 解剖學暨細胞生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-107-1.pdf 目前未授權公開取用 | 7.06 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。